a
a
Weather:
No weather information available
HomeHealthAccent Therapeutics Presents New Preclinical Data on Lead Clinical Programs ATX-295 and ATX-559 at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

Accent Therapeutics Presents New Preclinical Data on Lead Clinical Programs ATX-295 and ATX-559 at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

Novel KIF18A inhibitor, ATX-295, shows enriched activity in ovarian and TNBC preclinical models with whole genome doubling First-in-class DHX9 inhibitor, ATX-559, demonstrates potent activity in preclinical models of MSI-H and BRCA-deficient cancers Both ATX-295 and ATX-559 programs are…

No comments

Sorry, the comment form is closed at this time.

HomeHealthAccent Therapeutics Presents New Preclinical Data on Lead Clinical Programs ATX-295 and ATX-559 at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

Accent Therapeutics Presents New Preclinical Data on Lead Clinical Programs ATX-295 and ATX-559 at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

Novel KIF18A inhibitor, ATX-295, shows enriched activity in ovarian and TNBC preclinical models with whole genome doubling First-in-class DHX9 inhibitor, ATX-559, demonstrates potent activity in preclinical models of MSI-H and BRCA-deficient cancers Both ATX-295 and ATX-559 programs are…

No comments

Sorry, the comment form is closed at this time.

Translate »